Walter Fiedler

Apr 11, 2024 | fis.uke.de | Walter Fiedler

Research ExplorerPublicationsTherapy with hypomethlyating agents/venetoclax in patients w... Abstract Bibliographical data

Feb 12, 2024 | onlinelibrary.wiley.com | Keith W Pratz |Brian A. Jonas |Vinod Pullarkat |Michael J. Thirman |Jacqueline Garcia |Hartmut Döhner | +9 more

1 INTRODUCTION Acute myeloid leukemia (AML) is a heterogenous neoplasm characterized by proliferation of immature myeloid cells in bone marrow and peripheral blood, leading to failure of normal hematopoiesis.1 AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years.

May 12, 2023 | thelancet.com | Hartmut Döhner |Daniela Weber |Julia Krzykalla |Walter Fiedler

Background Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody–drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia. Methods This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria.